• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Molina Healthcare Inc

    5/1/25 4:26:20 PM ET
    $MOH
    Medical Specialities
    Health Care
    Get the next $MOH alert in real time by email
    S-8 1 s-8registrationstatement.htm S-8 Document

    As filed with the Securities and Exchange Commission on May 1, 2025
    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
     
    MOLINA HEALTHCARE, INC.
    (Exact name of registrant as specified in its charter)
    Delaware 13-4204626
    (State or other jurisdiction of
    incorporation or organization)
     (I.R.S. Employer
    Identification No.)
    200 Oceangate, Suite 100
    Long Beach,California
    (562) 435-3666
    (Address, including zip code, of principal executive offices)
    Molina Healthcare, Inc. 2025 Equity Incentive Plan
    (Full title of the plan)
    Jeff D. Barlow, Esq.
    Chief Legal Officer
    and Secretary
    Molina Healthcare, Inc.
    200 Oceangate, Suite 100
    Long Beach, California 90802
    (562) 435-3666
    (Name, address and telephone number, including area code, of agent for service)
    Copy to:
    David Zaheer
    Jenna B. Cooper
    10250 Constellation Blvd., Suite 1100
    Los Angeles, CA 90067
    (424) 653-5500


    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large Accelerated Filer  ☒                 Accelerated Filer ☐

    Non-Accelerated Filer ☐                 Smaller reporting company ☐


    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Exchange Act. ☐




    Explanatory Note
    This Registration Statement on Form S-8 is being filed for the purpose of registering (i) 1,795,000 shares of common stock, par value $0.001 per share (the “Common Stock”), of Molina Healthcare, Inc. (the “Registrant”), reserved for issuance under the Registrant’s 2025 Equity Incentive Plan (the “2025 Plan”) and (ii) an additional 1,016,729 shares of Common Stock that may become available for issuance under the 2025 Plan pursuant to the terms thereof.


    PART I
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
    The information called for in Part I of Form S-8 is not being filed with or included in this Registration Statement (by incorporation by reference or otherwise) in accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”).

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
    Item 3. Incorporation of Documents by Reference.
    The following documents filed or to be filed (other than portions of those documents furnished or otherwise not deemed filed) by the Registrant with the Commission are hereby incorporated by reference in this Registration Statement:
    (a) The Registrant's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on February 11, 2025 (File No. 001-31719) (the “Form 10-K”);
    (b) The Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the Commission on April 24, 2025 (File No. 001-31719), and the Registrant’s Current Reports on Form 8-K filed with the Commission on February 21, 2025 and May 1, 2025; and
    (c) The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form S-1 filed with the Commission on December 30, 2002 (File No. 333-102268), relating to the Registrant's Common Stock, as updated by “Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934” filed as Exhibit 4.7 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and any amendment or report filed for the purpose of updating such description.
    All reports and other documents filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date hereof (except for any portions of the Registrant’s Current Reports on Form 8-K furnished pursuant to Item 2.02 and/or Item 7.01 thereof and any corresponding exhibits thereto not filed with the Commission) and prior to the filing of a post-effective amendment to this Registration Statement, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents or reports.
    Any statement contained in this Registration Statement, in an amendment hereto or in a document incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed amendment to this Registration Statement or in any document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement, except as to specific section of such statements as set forth therein.



    Under no circumstances shall any information furnished under Item 2.02 and/or Item 7.01 of Current Report on Form 8-K and any corresponding exhibits thereto be deemed incorporated herein by reference unless such Current Report on Form 8-K expressly provides to the contrary.

    Item 4. Description of Securities.
    Not applicable.

    Item 5. Interests of Named Experts and Counsel.
    Not applicable.

    Item 6. Indemnification of Directors and Officers.
    Section 102 of the General Corporation Law of the State of Delaware permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. The Registrant’s certificate of incorporation provides that a director of the Registrant shall not be personally liable to the Registrant or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director's duty of loyalty to the Registrant or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the Delaware Corporation Law, as currently in existence or hereafter amended, or (iv) for any transaction from which the director derived an improper personal benefit.
    As permitted by Section 145 of the Delaware General Corporation Law, the Registrant’s certificate of incorporation and bylaws provide that the Registrant shall indemnify its directors, officers, employees, and agents to the full extent permitted by the Delaware General Corporation Law, including in circumstances in which indemnification is otherwise discretionary under Delaware law.
    In addition, the Registrant has entered into separate indemnification agreements with its directors, officers, and certain employees which requires the Registrant, among other things, to indemnify them against certain liabilities which may arise by reason of their status as directors, officers, or other employees, as applicable. The Registrant also maintains a general liability insurance policy that covers certain liabilities of directors and officers of the Registrant arising out of claims based on acts or omissions in their capacities as directors or officers, as applicable.
    These indemnification provisions and the indemnification agreements entered into between the Registrant and its officers, directors, and certain employees may be sufficiently broad to permit indemnification of the Registrant’s officers, directors, and such employees for liabilities (including reimbursement of expenses incurred) arising under the Securities Act.

    Item 7. Exemption from Registration Claimed.
    Not applicable.





    Item 8. Exhibits.

    Exhibit NumberDescription of Exhibit
    4.1
    Certificate of Incorporation (incorporated by reference to Exhibit 3.2 to the Registration Statement on Form S-1 filed with the Commission on December 30, 2002).
    4.2
    Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.2 to the Registrant’s Annual Report on Form 10-K filed with the Commission on February 13, 2024).
    4.3
    Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to the Registrant’s Annual Report on Form 10-K filed with the Commission on February 13, 2024).
    4.4
    Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on December 26, 2023).
    5.1*
    Opinion of Latham & Watkins LLP.
    23.1*
    Consent of Ernst & Young LLP.
    23.2*
    Consent of Latham & Watkins LLP (included in Exhibit 5.1).
    24.1*
    Power of Attorney (included on signature page).
    99.1
    Molina Healthcare, Inc. 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on May 1, 2025).
    107.1*
    Filing Fee Table

    image_0.jpg
    *Filed herewith.


    Item 9. Undertakings.
    (a) The undersigned Registrant hereby undertakes:
    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement;
    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
    (ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as applicable, in the effective Registration Statement; and
    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;



    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the Registration Statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the Registration Statement; and
    (2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.




    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York on May 1, 2025.


    MOLINA HEALTHCARE, INC.
    By:/s/ Joseph M. Zubretsky
    Joseph M. Zubretsky
    Chief Executive Officer
    (Principal Executive Officer)


    SIGNATURES AND POWER OF ATTORNEY
    Each person whose signature appears below hereby constitutes and appoints Joseph M. Zubretsky and Jeff D. Barlow, or each of them singly, with full power to act without the other, such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him and in his name, place and stead, in any and all capacities, to sign this registration statement and any and all amendments, including post-effective amendments to this registration statement, and to file the same, with exhibits and schedules thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary or desirable to be done in connection therewith as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitute or substitutes may lawfully do or cause to be done by virtue hereof.
    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
    SignatureTitleDate
    /s/ Joseph M. ZubretskyChief Executive Officer and DirectorMay 1, 2025
    Joseph M. Zubretsky(Principal Executive Officer)
    /s/ Mark L. KeimChief Financial OfficerMay 1, 2025
    Mark L. Keim(Principal Financial Officer)
    /s/ Maurice S. HebertChief Accounting OfficerMay 1, 2025
    Maurice S. Hebert(Principal Accounting Officer)
    /s/ Barbara L. BrasierDirectorMay 1, 2025
    Barbara L. Brasier



    /s/ Leo P. GrohowskiDirectorMay 1, 2025
    Leo P. Grohowski
    /s/ Stephen H. LockhartDirectorMay 1, 2025
    Stephen H. Lockhart
    /s/ Steven J. OrlandoDirectorMay 1, 2025
    Steven J. Orlando
    /s/ Ronna E. RomneyDirectorMay 1, 2025
    Ronna E. Romney
    /s/ Richard M. SchapiroDirectorMay 1, 2025
    Richard M. Schapiro
    /s/ Dale B. WolfChairman of the BoardMay 1, 2025
    Dale B. Wolf
    /s/ Richard C. ZoreticDirectorMay 1, 2025
    Richard C. Zoretic



    Get the next $MOH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MOH

    DatePrice TargetRatingAnalyst
    4/22/2025$414.00Outperform
    Bernstein
    4/15/2025$375.00Outperform → Neutral
    Robert W. Baird
    3/5/2025$295.00 → $372.00Equal Weight → Overweight
    Wells Fargo
    12/17/2024$378.00 → $350.00Neutral
    Analyst
    5/30/2024$405.00Outperform
    Robert W. Baird
    3/28/2024$439.00Neutral → Underperform
    BofA Securities
    3/6/2024$437.00Equal Weight
    Barclays
    2/15/2024$367.00 → $420.00Underweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $MOH
    Financials

    Live finance-specific insights

    See more
    • Molina Healthcare Reports First Quarter 2025 Financial Results

      Reaffirms Full Year 2025 Guidance Molina Healthcare, Inc. (NYSE:MOH) (the "Company") today reported first quarter 2025 GAAP earnings per diluted share of $5.45 and adjusted earnings per diluted share of $6.08. Financial results are summarized below:   Three months ended   March 31,   2025   2024         (In millions, except per-share results) Premium Revenue $10,628   $9,504 Total Revenue $11,147   $9,931         GAAP:       Net Income $298   $301 EPS – Diluted $5.45   $5.17 Medical Care Ratio (MCR) 89.2%   88.5% G&A Ratio 6.9%   7.2

      4/23/25 4:15:00 PM ET
      $MOH
      Medical Specialities
      Health Care
    • Molina Healthcare Announces First Quarter 2025 Earnings Release and Conference Call Dates

      Molina Healthcare, Inc. (NYSE:MOH) today announced it will issue its earnings release for the first quarter ending March 31, 2025, after the market closes on Wednesday, April 23, 2025, and will host a conference call and webcast to discuss the earnings release on Thursday, April 24, 2025, at 8:00 a.m. Eastern Time. To access this interactive teleconference, dial (877) 883-0383 and enter the confirmation number, 3317326. A telephonic replay of the conference call will be available through Thursday, May 1, 2025, by dialing (877) 344-7529 and entering the confirmation number, 6106565. A live broadcast of Molina Healthcare's conference call will be available on the Company's investor relations

      3/5/25 9:00:00 AM ET
      $MOH
      Medical Specialities
      Health Care
    • Molina Healthcare Reports Fourth Quarter and Year-End 2024 Financial Results

      Introduces Full Year 2025 Revenue and Earnings Guidance Molina Healthcare, Inc. (NYSE:MOH) (the "Company") today reported fourth quarter 2024 GAAP earnings per diluted share of $4.44 and adjusted earnings per diluted share of $5.05. The Company also reported full year 2024 GAAP earnings per diluted share of $20.42 and adjusted earnings per diluted share of $22.65. Financial results are summarized below:   Three months ended   Year ended   December 31,   December 31,   2024   2023   2024   2023                 (In millions, except per-s

      2/5/25 4:15:00 PM ET
      $MOH
      Medical Specialities
      Health Care

    $MOH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Molina Healthcare Inc

      SC 13G/A - MOLINA HEALTHCARE, INC. (0001179929) (Subject)

      11/14/24 1:22:34 PM ET
      $MOH
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Molina Healthcare Inc

      SC 13G - MOLINA HEALTHCARE, INC. (0001179929) (Subject)

      11/12/24 12:53:29 PM ET
      $MOH
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Molina Healthcare Inc

      SC 13G/A - MOLINA HEALTHCARE, INC. (0001179929) (Subject)

      11/8/24 10:34:33 AM ET
      $MOH
      Medical Specialities
      Health Care

    $MOH
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Molina Healthcare Inc

      SCHEDULE 13G - MOLINA HEALTHCARE, INC. (0001179929) (Subject)

      5/14/25 10:45:26 AM ET
      $MOH
      Medical Specialities
      Health Care
    • SEC Form S-8 filed by Molina Healthcare Inc

      S-8 - MOLINA HEALTHCARE, INC. (0001179929) (Filer)

      5/1/25 4:26:20 PM ET
      $MOH
      Medical Specialities
      Health Care
    • Molina Healthcare Inc filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - MOLINA HEALTHCARE, INC. (0001179929) (Filer)

      5/1/25 4:17:16 PM ET
      $MOH
      Medical Specialities
      Health Care

    $MOH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Molina Healthcare Reports First Quarter 2025 Financial Results

      Reaffirms Full Year 2025 Guidance Molina Healthcare, Inc. (NYSE:MOH) (the "Company") today reported first quarter 2025 GAAP earnings per diluted share of $5.45 and adjusted earnings per diluted share of $6.08. Financial results are summarized below:   Three months ended   March 31,   2025   2024         (In millions, except per-share results) Premium Revenue $10,628   $9,504 Total Revenue $11,147   $9,931         GAAP:       Net Income $298   $301 EPS – Diluted $5.45   $5.17 Medical Care Ratio (MCR) 89.2%   88.5% G&A Ratio 6.9%   7.2

      4/23/25 4:15:00 PM ET
      $MOH
      Medical Specialities
      Health Care
    • Molina Healthcare Wins Illinois Contract to Provide a Dual Eligible Special Needs Plan

      Molina Healthcare, Inc. (NYSE:MOH) ("Molina" or the "Company") announced today that the Company's subsidiary, Molina Healthcare of Illinois, Inc., was one of four managed care organizations awarded a contract by the Illinois Department of Healthcare and Family Services to provide a Fully Integrated Dual Eligible Special Needs Plan (D-SNP). This contract will replace the State's Medicare-Medicaid Alignment Initiative (MMAI) demonstration program, which currently serves approximately 73,000 beneficiaries. The go-live date for the new contract is expected to be January 1, 2026. The contract is expected to have an initial term of four years, with the option to extend the contract from the init

      3/18/25 9:00:00 AM ET
      $MOH
      Medical Specialities
      Health Care
    • Molina Healthcare Announces First Quarter 2025 Earnings Release and Conference Call Dates

      Molina Healthcare, Inc. (NYSE:MOH) today announced it will issue its earnings release for the first quarter ending March 31, 2025, after the market closes on Wednesday, April 23, 2025, and will host a conference call and webcast to discuss the earnings release on Thursday, April 24, 2025, at 8:00 a.m. Eastern Time. To access this interactive teleconference, dial (877) 883-0383 and enter the confirmation number, 3317326. A telephonic replay of the conference call will be available through Thursday, May 1, 2025, by dialing (877) 344-7529 and entering the confirmation number, 6106565. A live broadcast of Molina Healthcare's conference call will be available on the Company's investor relations

      3/5/25 9:00:00 AM ET
      $MOH
      Medical Specialities
      Health Care

    $MOH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Orlando Steven J sold $318,580 worth of shares (1,000 units at $318.58) (SEC Form 4)

      4 - MOLINA HEALTHCARE, INC. (0001179929) (Issuer)

      5/5/25 4:36:49 PM ET
      $MOH
      Medical Specialities
      Health Care
    • Director Grohowski Leo P was granted 118 shares (SEC Form 4)

      4 - MOLINA HEALTHCARE, INC. (0001179929) (Issuer)

      5/2/25 4:43:52 PM ET
      $MOH
      Medical Specialities
      Health Care
    • New insider Grohowski Leo P claimed no ownership of stock in the company (SEC Form 3)

      3 - MOLINA HEALTHCARE, INC. (0001179929) (Issuer)

      5/2/25 4:40:53 PM ET
      $MOH
      Medical Specialities
      Health Care

    $MOH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bernstein initiated coverage on Molina Healthcare with a new price target

      Bernstein initiated coverage of Molina Healthcare with a rating of Outperform and set a new price target of $414.00

      4/22/25 7:34:03 AM ET
      $MOH
      Medical Specialities
      Health Care
    • Molina Healthcare downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Molina Healthcare from Outperform to Neutral and set a new price target of $375.00

      4/15/25 9:27:54 AM ET
      $MOH
      Medical Specialities
      Health Care
    • Molina Healthcare upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Molina Healthcare from Equal Weight to Overweight and set a new price target of $372.00 from $295.00 previously

      3/5/25 7:37:05 AM ET
      $MOH
      Medical Specialities
      Health Care